查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1419132

医院获得性感染治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按药物类别、感染类型、配销通路和地理位置

Hospital Acquired Infection Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Class, Infection Type, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 171 Pages | 商品交期: 1-5个工作天内

价格
简介目录

全球医院获得性感染治疗市场预计将从2022年的150.99亿美元增至2030年的199.78亿美元。预计2022年至2030年该市场将以3.6%的CAGR成长。

推动市场成长的关键因素包括医院获得性感染（HAI）的高盛行率以及对病人安全和优质照护的日益关注。然而，抗菌素抗药性的威胁阻碍了市场的成长。

医院获得性感染治疗市场的市场驱动因素

中心静脉导管相关的血流感染、导管相关的泌尿道感染和呼吸器相关的肺炎是医疗保健相关感染 (HAI) 的几个例子。这些感染也可能发生在手术部位。根据美国疾病管制与预防中心（CDC）2021年发布的《2020年国家和州医疗保健相关感染进展报告》，中心静脉导管相关血流感染、耐甲氧西林金黄色葡萄球菌（MRSA）菌血症和呼吸器病例2019 年至 2020 年间，美国相关事件分别增加了 24%、35% 和 15%。

此外，根据国家医疗安全网路 (NHSN) 2022 年 1 月的报告，泌尿道感染 (UTI) 是第五大常见的医疗保健相关感染类型。泌尿道感染占急诊医院病情的 9.5% 以上。导管相关性泌尿道感染 (CAUTI) 是由用于从膀胱排出尿液的导尿管引起的。 CAUTI 是住院 UTI 患者中最常见的感染之一。根据美国疾病管制与预防中心 (CDC) 的数据，近 75% 的感染与导尿管有关。住院期间，15%至25%的住院患者必须使用导尿管。长期使用导尿管是患有 CAUTI 最主要的危险因子。 CAUTI 併发症会导致患者痛苦、住院时间延长、治疗费用增加，甚至死亡。

医院获得性感染治疗市场的机会

新型抗菌药物（包括抗生素、抗真菌药物和抗病毒药物）的持续开发，为对抗 HAI、解决新出现的抗药性模式和扩大治疗方案提供了机会。此外，医疗机构、製药公司和研究组织之间的合作措施为发现新的治疗标靶、发现抗生素和开发下一代感染治疗策略提供了机会。

医院获得性感染治疗市场：细分概述

医院感染治疗市场依药品类别分为抗菌、抗病毒、抗真菌等。抗菌药物领域在 2022 年占据最大的市场份额，预计 2022-2030 年CAGR最高。

本院获得性感染治疗市场依感染类型分为泌尿道感染、呼吸器相关性肺炎、手术部位感染、血流感染等院内感染。泌尿道感染细分市场在 2022 年占据最大的市场份额。然而，预计 2022 年至 2030 年呼吸器相关肺炎细分市场的CAGR最高。

医院感染治疗市场依配销通路分为医院药局、零售药局、电子商务等。 2022年，医院药局细分市场占据最大的市场份额，预计该细分市场在2022-2030年期间复合CAGR最高。

医院获得性感染治疗市场：地理概况

据估计，2022年至2030年，亚太地区的CAGR最高。印度和中国等亚太国家的医院获得性感染治疗市场成长潜力巨大。该地区的发展中国家改善了医疗基础设施，增加了医疗支出，并越来越注重采用先进的医疗技术，为市场扩张提供了机会。

2022年，北美在全球医院获得性感染治疗市场中占据最大份额。美国医院感染发生率很高，这推动了医院获得性感染治疗市场的成长。根据 CDC 的数据，在任何一天，大约每 31 名医院患者中就有 1 名至少患有一次 HAI。同样，根据疾病预防和健康促进办公室的数据，医院感染和其他感染可导致败血症，在美国每年导致 170 万例病例和 27 万人死亡。因此，美国人医院感染的高盛行率推动了医院获得性感染治疗市场的成长。

此外，根据美国医疗保险和医疗补助服务中心的数据，2021年美国国家医疗保健支出将增加2.7%，达到4.3兆美元，即人均12,914美元。此外，医疗支出占国内生产毛额的18.3%。此外，根据美国卫生与公众服务部的数据，2019年至2028年，国家卫生支出预计将以每年平均5.4%的速度成长，到2028年预计将达到6.2兆美元。增加医院感染药物开发相关研究的各种资金来源，刺激医院获得性感染治疗的需求。

在准备医院获得性感染治疗市场报告时提到的一些主要一手和二手来源包括世界银行数据、国家卫生服务体系 (NHS)、FDA（食品和药物管理局）、EMA（欧洲药品管理局）和WHO （世界卫生组织）。

目录

第 1 章：简介

  • 研究范围
  • 市场定义、假设与限制
  • 市场区隔

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：医院获得性感染治疗市场格局

  • 概述
  • PEST分析

第 5 章：医院获得性感染治疗市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：医院获得性感染治疗市场 - 全球市场分析

  • 医院获得性感染治疗 - 全球市场概览
  • 医院获得性感染治疗 - 全球市场和 2030 年预测

第 7 章：医院获得性感染治疗市场 - 收入分析 - 按药物类别，2020-2030 年

  • 概述
  • 抗菌药物
  • 抗病毒药物
  • 抗真菌药物
  • 其他的

第 8 章：医院获得性感染治疗市场 - 收入分析 - 按感染类型，2020-2030 年

  • 概述
  • 泌尿道感染
  • 呼吸器相关肺炎
  • 手术部位感染
  • 血流感染
  • 其他医院感染

第 9 章：医院获得性感染治疗市场 - 收入分析 - 按配销通路，2020-2030 年

  • 概述
  • 医院药房
  • 零售药局
  • 电子商务
  • 其他的

第 10 章：医院获得性感染治疗市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 13 章：医院获得性感染治疗市场 - 主要公司概况

  • Merck and Co. Inc.

注意 - 将为以下公司列表提供类似信息

  • 辉瑞公司
  • 艾伯维公司
  • 帕拉泰克製药公司
  • 尤吉亚美国有限责任公司
  • 雅培实验室
  • 坎伯兰製药公司
  • Innoviva 专业治疗公司
  • 西普拉有限公司
  • 礼来公司

第 14 章：附录

  • 词彙表
  • 关于 Insight Partners
  • 市场情报云
简介目录
Product Code: TIPRE00029976

The global hospital-acquired infection treatment market is expected to reach US$ 19.978 billion in 2030 from US$ 15.099 billion in 2022. The market is estimated to grow with a CAGR of 3.6% from 2022 to 2030.

The key factors driving the market's growth include the high prevalence of hospital-acquired infections (HAI) and the growing focus on patient safety and quality care. However, the threat of antimicrobial resistance hinders market growth.

Market Drivers of the Hospital-Acquired Infection Treatment Market

Central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia are a few examples of healthcare-associated infections (HAIs). These infections can also arise at surgical sites. According to the Centers for Disease Control and Prevention (CDC) report "2020 National and State Healthcare-Associated Infections Progress Report" published in 2021, cases of central line-associated bloodstream infections, Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and ventilator-associated events increased by 24%, 35%, and 15%, respectively, in the US between 2019 and 2020.

Furthermore, According to the January 2022 report from the National Healthcare Safety Network (NHSN), urinary tract infections (UTIs) are the fifth most common type of healthcare-associated infection. UTIs account for more than 9.5% of acute care hospital conditions. Catheter-associated urinary Tract Infection (CAUTI) is caused by urinary catheters used to drain urine from the bladder. CAUTI is one of the most frequent infections among hospitalized UTI patients. According to the Centers for Disease Control and Prevention (CDC), nearly 75% of infections are related to a urinary catheter. During hospital stays, 15% to 25% of hospitalized patients must use urinary catheters. Prolonged urinary catheter use is the most major risk factor for getting CAUTI. CAUTI complications entail patient suffering, prolonged hospital stays, increased treatment costs, and even death.

Opportunities in the Hospital-Acquired Infection Treatment Market

The continuous development of novel antimicrobial agents, including antibiotics, antifungals, and antivirals, presents opportunities for combating HAIs, addressing emerging resistance patterns, and expanding the armamentarium of treatment options. Additionally, collaborative initiatives among healthcare institutions, pharmaceutical companies, and research organizations present opportunities for discovering novel therapeutic targets, discovering antibiotics, and developing next-generation infection treatment strategies.

Hospital Acquired Infection Treatment Market: Segmental Overview

The hospital acquired infection treatment market, by drug class, is segmented into antibacterial, antiviral, antifungal, and others. The antibacterial drugs segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022-2030.

The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held the largest market share in 2022. However, the ventilator-associated pneumonia segment is anticipated to register the highest CAGR from 2022 to 2030.

The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospital pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022-2030.

Hospital Acquired Infection Treatment Market: Geographical Overview

Asia Pacific is estimated to register the highest CAGR from 2022 to 2030. Countries in the Asia Pacific, such as India and China, hold significant potential for the hospital-acquired infection treatment market growth. Developing countries in the region with improving healthcare infrastructure, increasing healthcare expenditure, and a rising focus on adopting advanced medical technologies offer opportunities for market expansion.

In 2022, North America held the largest share of the global hospital-acquired infection treatment market. The US has a high prevalence of HAI, which propels the hospital-acquired infection treatment market growth. As per the CDC, on any given day, about 1 in 31 hospital patients has at least one HAI. Similarly, according to the Office of Disease Prevention and Health Promotion, HAIs and other infections can lead to sepsis, and it causes 1.7 million illness cases and 270,000 deaths per year in the US. Thus, the high prevalence of HAI among people in the US fuels the hospital-acquired infection treatment market growth.

Furthermore, according to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US will increase by 2.7 percent in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Also, health spending accounted for 18.3 percent of the nation's Gross Domestic Product. Furthermore, according to the US Department of Health & Human Services, National health spending is expected to grow at a 5.4% annual rate from 2019 to 2028, and it is expected to reach US$ 6.2 trillion by 2028. The rising health expenditure is estimated to increase various funding sources in the research related to the development of HAI drugs, fueling the demand for hospital-acquired infection treatment.

A few of the major primary and secondary sources referred to while preparing the report on the hospital-acquired infection treatment market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Hospital Acquired Infection Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Hospital Acquired Infection Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Hospital Acquired Infection Treatment Market - Global Market Analysis

  • 6.1 Hospital Acquired Infection Treatment - Global Market Overview
  • 6.2 Hospital Acquired Infection Treatment - Global Market and Forecast to 2030

7. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million) - By Drug Class, 2020-2030

  • 7.1 Overview
  • 7.2 Antibacterial Drugs
  • 7.3 Antiviral Drugs
  • 7.4 Antifungal Drugs
  • 7.5 Others

8. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million) - By Infection Type, 2020-2030

  • 8.1 Overview
  • 8.2 Urinary Tract Infections
  • 8.3 Ventilator-associated Pneumonia
  • 8.4 Surgical Site Infections
  • 8.5 Bloodstream Infections
  • 8.6 Other Hospital Infections

9. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 E-Commerce
  • 9.5 Others

10. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Hospital Acquired Infection Treatment Market Overview
    • 10.1.2 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts to 2030
    • 10.1.3 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Drug Class
    • 10.1.4 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Infection Type
    • 10.1.5 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Hospital Acquired Infection Treatment Market
        • 10.1.6.1.1 United States Hospital Acquired Infection Treatment Market, by Drug Class
        • 10.1.6.1.2 United States Hospital Acquired Infection Treatment Market, by Infection Type
        • 10.1.6.1.3 United States Hospital Acquired Infection Treatment Market, by Distribution Channel
      • 10.1.6.2 Canada Hospital Acquired Infection Treatment Market
        • 10.1.6.2.1 Canada Hospital Acquired Infection Treatment Market, by Drug Class
        • 10.1.6.2.2 Canada Hospital Acquired Infection Treatment Market, by Infection Type
        • 10.1.6.2.3 Canada Hospital Acquired Infection Treatment Market, by Distribution Channel
      • 10.1.6.3 Mexico Hospital Acquired Infection Treatment Market
        • 10.1.6.3.1 Mexico Hospital Acquired Infection Treatment Market, by Drug Class
        • 10.1.6.3.2 Mexico Hospital Acquired Infection Treatment Market, by Infection Type
        • 10.1.6.3.3 Mexico Hospital Acquired Infection Treatment Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Hospital Acquired Infection Treatment Market - Key Company Profiles

  • 13.1 Merck and Co. Inc.
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 13.2 Pfizer Inc
  • 13.3 AbbVie Inc
  • 13.4 Paratek Pharmaceutical Inc
  • 13.5 Eugia US LLC
  • 13.6 Abbott Laboratories
  • 13.7 Cumberland Pharmaceuticals Inc
  • 13.8 Innoviva Specialty Therapeutics Inc
  • 13.9 Cipla Ltd
  • 13.10 Eli Lilly and Company

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud